Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
February, 2026
February 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
232425262728  
Lp(a) Testing in Primary Prevention: Cost-Effective Strategy to Reduce Cardiovascular Risk
Sep 14, 2025, 14:36

Lp(a) Testing in Primary Prevention: Cost-Effective Strategy to Reduce Cardiovascular Risk

Atherosclerosis has shared a post on LinkedIn:

“Lp(a) Testing: A Cost-Saving Tool for Cardiovascular Prevention

High Lp(a) levels are a known cardiovascular risk factor, but is testing for Lp(a) worth it from a healthcare perspective?
A recent microsimulation study modeled 10,000 adults aged 40–69 without prior CVD from the UK Biobank. The study evaluated Lp(a) testing in individuals not initially high-risk. Those with Lp(a) ≥105 nmol/L were reclassified as high-risk and received statins and blood pressure–lowering therapy.

Key findings:

  • Out of 10,000 individuals, 1,807 had their treatment modified based on Lp(a).
  • 217–255 quality-adjusted life years gained in Australia and the UK.
  • Cost-effectiveness ratios: $12,134 AUD (cost-effective) and −£3,491 GBP (cost-saving).
  • From a societal perspective, testing saved $85 AUD and £263 GBP per person.
  • Modeling across multiple countries showed Lp(a) testing to be cost-saving everywhere.

Takeaway: Lp(a) testing in primary prevention reclassifies risk, guides therapy, and saves costs—supporting its adoption as a preventive strategy against CVD.

This study makes a compelling case for integrating Lp(a) measurement into routine cardiovascular risk assessment.”

Title: Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis

Author: Jedidiah I. Morton, Florian Kronenberg, Magdalena Daccord, Nicola Bedlington, Marius Geant, Tobias Silberzahn, Zhenyue Chen, Jean-Luc Eisele, Bogi Eliasen, Mariko Harada-Shiba, Marc Rijken, Albert Wiegman, George Thanassoulis, Pia R. Kamstrup, Iñaki Gutierrez-Ibarluzea, Pablo Coral, Raul D. Santos, Erik Stroes, Michal Vrablik, Gerald F. Watts, Christie M. Ballantyne, Samia Mor, Børge G. Nordestgaard, Kausik K. Ray, Stephen J. Nicholls, Zanfina Ademi

Prevention

Read the full article here.

Stay updated with Hemostasis Today.

Albert Wiegman Atherosclerosis Bogi Eliasen Børge G. Nordestgaard cardiovascular risk Christie M. Ballantyne Erik Stroes Florian Kronenberg George Thanassoulis Gerald F. Watts Hematology Hemostasis Hemostasis Today Iñaki Gutierrez-Ibarluzea Jean-Luc Eisele Jedidiah I. Morton Kausik K. Ray Lp(a) Magdalena Daccord Marc Rijken Mariko Harada-Shiba Marius Geant Michal Vrablik Nicola Bedlington Pablo Coral Pia R. Kamstrup Prevention Raul D. Santos Samia Mor Stephen J Nicholls Tobias Silberzahn Zanfina Ademi Zhenyue Chen
NewsFeed